Steve Blumenthal
Presidente presso Cynvec LLC
Profilo
Steve Blumenthal is the founder of Synchron Corp.
which was founded in 1980.
He is currently the Chairman of Cynvec LLC.
He previously worked as a Principal at Bache & Co., Inc. Mr. Blumenthal received an undergraduate degree from the State University of New York at Buffalo.
Posizioni attive di Steve Blumenthal
| Società | Posizione | Inizio |
|---|---|---|
Cynvec LLC
 Cynvec LLC Pharmaceuticals: MajorHealth Technology Cynvec LLC develops oncolytic therapeutics for the treatment of cancer. It offers cancer treatment platform to activate the body’s own immune system to safely attack tumors and prevent or slow cancer recurrence. The firm develops CYN-101, a bioengineered Sindbis viral vector vaccine expressing the NY-ESO-1 tumor associated antigen for the treatment of late-stage ovarian cancer; and an immunotherapeutic vaccine for multiple possible cancer targets. The company was founded in 2004 and is headquartered in New York, NY. | Presidente | 17/09/2009 |
Precedenti posizioni note di Steve Blumenthal
| Società | Posizione | Fine |
|---|---|---|
| Synchron Corp. | Fondatore | - |
Bache & Co., Inc.
 Bache & Co., Inc. Investment Banks/BrokersFinance Bache & Co., Inc. provides stock brokerage and investment banking services. The private company is based in Buffalo, NY. | Corporate Officer/Principal | - |
Formazione di Steve Blumenthal
| State University of New York at Buffalo | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
Cynvec LLC
Cynvec LLC Pharmaceuticals: MajorHealth Technology Cynvec LLC develops oncolytic therapeutics for the treatment of cancer. It offers cancer treatment platform to activate the body’s own immune system to safely attack tumors and prevent or slow cancer recurrence. The firm develops CYN-101, a bioengineered Sindbis viral vector vaccine expressing the NY-ESO-1 tumor associated antigen for the treatment of late-stage ovarian cancer; and an immunotherapeutic vaccine for multiple possible cancer targets. The company was founded in 2004 and is headquartered in New York, NY. | Health Technology |
Bache & Co., Inc.
Bache & Co., Inc. Investment Banks/BrokersFinance Bache & Co., Inc. provides stock brokerage and investment banking services. The private company is based in Buffalo, NY. | Finance |
| Synchron Corp. |
- Borsa valori
- Insiders
- Steve Blumenthal
